LAMP-News - 500 Beiträge pro Seite

[HolgiNils]

LAM PHARMACEUTICAL CORP - LAM IPM(TM) Wound Gel Ulcer Study Selected forPresentation at The - 15th Annual Symposium on Advanced Wound Care, April 27-30,2002
New York, New York, Mar 04, 2002 (Market News Publishing via COMTEX) -- LAM Pharmaceutical Corp., http://www.lampharm.com.

Ronald E. Reece, M.D., Principle Investigator for the LAM IPM(TM) Wound Gel effectiveness study announced that the study abstract has been selected for presentation at The 15th Annual Symposium on Advanced Wound Care in Baltimore, Maryland, April 27-30, 2002. The 24-week study reported a healing rate of 88% on 53 refractory (hard-to-heal) skin ulcers treated with LAM IPM(TM) Wound Gel. Study inclusion criteria required that patients had an ulcer that had not responded to other forms of treatment for at least four weeks prior to enrollment in this study. The study concluded that LAM IPM(TM) Wound Gel created an optimal environment for wound healing to occur.

Alan Drizen, LAM CEO commented, "We are very proud of the study conducted by Dr. Reece and honored that it has been selected for presentation by the Society of Advanced Wound Care."

The Annual Symposium on Advanced Wound Care has become known as the premier wound care conference in the United States drawing over 1500 healthcare professionals with over 70 participating pharmaceutical companies.

LAM also announced it has launched a new web site which contains up-to-date information on the company and its products. LAM invites all shareholders and potential shareholders to peruse the site at http://www.lampharm.com

LAM Pharmaceutical Corp. is a biomedical company with laboratories in Lewiston, New York, and a business office in Toronto. LAM focuses on the development and commercialization of novel wound healing and transdermal drug delivery systems that offer patients, among other benefits, safer and more effective treatment for a variety of serious diseases. The technology is based on an original Ionic Polymer Matrix(TM) technology (IPM(TM)), a proprietary and patented combination (a total of nine U.S. issued patents) of electrically charged and non-charged molecules with wound-healing properties. IPM(TM) technology combines with well-established drugs, allowing for the sustained delivery of greater amounts to the target areas than is otherwise possible and thus prolonging therapeutic activity.

The main ingredient of the Ionic Polymer Matrix(TM) technology is a derivative of hyaluronic acid, a molecule normally found in the skin and joints of bones. Hyaluronic acid is a non-immunogenic (the body does not react to it) and it is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars) to optimize tissue repair and prevent tissue aging. As well, hyaluronic acid is present in high concentration in fetal skin where wound healing is rapid and leaves little scarring.

LAM IPM(TM) Wound Gel is a clear, viscous, aqueous, odorless gel composed principally of sodium hyaluronate, a derivative salt of Hyaluronic acid. LAM IPM(TM) Wound Gel has demonstrated in both human and animal trials to be of significant value in the management of certain skin ulcers and wounds where maintaining a moist environment is supportive of the healing process. In human skin, Hyaluronic acid is involved in such important biological functions as tissue hydration and proteoglycan organization (formation of proteins and sugars).

As of December 31, 2001, LAM had nine issued patents in the United States. LAM IPM(TM) Wound Gel is protected by one or more of the following patents: 5,887,880; 6,120,804; 6,007,843; 6,063,405. All referenced patents have been issued to LAM Pharmaceutical, Corp. by the United States Patent Office and have subsequently been filed on a global basis.

The Company`s list of products under development include the following:

LAM IPM(TM) -- Extreme Dry Skin Formula -- A gel formula designed to saturate the stratum corneum, to relieve the symptoms of eczema, dermatitis and extremely dry skin.

LAM IPM(TM) -- Female Sexual Dysfunction Matrix -- a product that provides enhanced lubrication while also allowing the external structures of the female genitalia to be flushed with greater blood supply.

LAM IPM(TM) -- Motion Sickness Matrix -- a product currently under development, which is a topically applied delivery system, using a patch, of a well-known motion sickness drug.

LAM IPM(TM) -- Arthritic Pain Matrix -- is a clear aqueous gel that contains a well proven off patent drug.

For more information please visit our website at http://www.lampharm.com or send us an e-mail at infolampharm.com to receive the latest information and press releases.

Statements in this press release regarding our business which are not historical facts are "forward-looking statements" that involve risks and uncertainties which could cause the Company`s actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, but are not limited to uncertainties relating to the need for additional funds and corporate partners, product liability, dependence on third parties for manufacturing and marketing, the early stage of products being marketed or under development, patent risk and competition.

Press Contact: Barry S. Kaplan

Company Contact: Anthony Vespa

Toll Free in N. America (877) LAM-7717

[phone]


CONTACT: Tel [phone]

Fax [phone]
Website: http://www.lampharm.com

TEL: +1-877-LAM-7717 Anthony Vespa of LAM Pharmaceutical Corp.
TEL: [phone]
TEL: [phone]
FAX: [phone]

TEL: [phone] Barry S. Kaplan of Barry Kaplan Associates
FAX: [phone]
EMAIL: [e-mail], for LAM Pharmaceutical Corp.
INET : http://www.lampharm.com

URL: http://www.lampharm.com
MarketbyFax(tm) - To get the NEWS as it happens, call [phone].

(C) 2002 Market News Publishing Inc.

[Apetitaeffchen]

Kann es sein, dass Du das Datum der Veröffentlichung, na sagen wir mal ei wenig frisiert hast??

[HolgiNils]

@Apetitaeffchen
Nicht im entferntesten!
Die Meldung wird von ALPHATRADE ganz frisch angezeigt.
Wie kommst Du auf den Bolzen ?

[HolgiNils]

Schau halt mal:
http://egate.alphatrade.com/com.alphatrade.servlet.http.news…

alles in eine Zeile des IE kopieren und ab dafür!

[Apetitaeffchen]

@holgi

Das ist vom 27.02!




Latest News

--------------------------------------------------------------------------------
LAM IPM(TM) Wound Gel Ulcer Study Selected for Presentation at The 15th Annual Symposium on Advanced Wound Care, April 27-30, 2002


LEWISTON, N.Y., Feb 27, 2002 (Canada NewsWire via COMTEX) -- LAM Pharmaceutical
Corp. (OTC Bulletin Board: LAMP; Frankfurt Stock Exchange: LAM),
http://www.lampharm.com.

Ronald E. Reece, M.D., Principle Investigator for the LAM IPM(TM) Wound Gel
effectiveness study announced today that the study abstract has been selected
for presentation at The 15th Annual Symposium on Advanced Wound Care in
Baltimore, Maryland, April 27-30, 2002. The 24-week study reported a healing
rate of 88% on 53 refractory (hard-to-heal) skin ulcers treated with LAM IPM(TM)
Wound Gel. Study inclusion criteria required that patients had an ulcer that had
not responded to other forms of treatment for at least four weeks prior to
enrollment in this study. The study concluded that LAM IPM(TM) Wound Gel created
an optimal environment for wound healing to occur.

Alan Drizen, LAM CEO commented, "We are very proud of the study conducted by Dr.
Reece and honored that it has been selected for presentation by the Society of
Advanced Wound Care."

The Annual Symposium on Advanced Wound Care has become known as the premier
wound care conference in the United States drawing over 1500 healthcare
professionals with over 70 participating pharmaceutical companies.

LAM also announced it has launched a new web site which contains up-to-date
information on the company and its products. LAM invites all shareholders and
potential shareholders to peruse the site at http://www.lampharm.com

LAM Pharmaceutical Corp. is a biomedical company with laboratories in Lewiston,
New York, and a business office in Toronto. LAM focuses on the development and
commercialization of novel wound healing and transdermal drug delivery systems
that offer patients, among other benefits, safer and more effective treatment
for a variety of serious diseases. The technology is based on an original Ionic
Polymer Matrix(TM) technology (IPM(TM)), a proprietary and patented combination
(a total of nine U.S. issued patents) of electrically charged and non-charged
molecules with wound-healing properties. IPM(TM) technology combines with
well-established drugs, allowing for the sustained delivery of greater amounts
to the target areas than is otherwise possible and thus prolonging therapeutic
activity.

The main ingredient of the Ionic Polymer Matrix(TM) technology is a derivative
of hyaluronic acid, a molecule normally found in the skin and joints of bones.
Hyaluronic acid is a non-immunogenic (the body does not react to it) and it is
involved in such important biological functions as tissue hydration and
proteoglycan organization (formation of proteins and sugars) to optimize tissue
repair and prevent tissue aging. As well, hyaluronic acid is present in high
concentration in fetal skin where wound healing is rapid and leaves little
scarring.

LAM IPM(TM) Wound Gel is a clear, viscous, aqueous, odorless gel composed
principally of sodium hyaluronate, a derivative salt of Hyaluronic acid. LAM
IPM(TM) Wound Gel has demonstrated in both human and animal trials to be of
significant value in the management of certain skin ulcers and wounds where
maintaining a moist environment is supportive of the healing process. In human
skin, Hyaluronic acid is involved in such important biological functions as
tissue hydration and proteoglycan organization (formation of proteins and
sugars).

As of December 31, 2001, LAM had nine issued patents in the United States. LAM
IPM(TM) Wound Gel is protected by one or more of the following patents:
5,887,880; 6,120,804; 6,007,843; 6,063,405. All referenced patents have been
issued to LAM Pharmaceutical, Corp. by the United States Patent Office and have
subsequently been filed on a global basis.

The Company`s list of products under development include the following:

LAM IPM(TM) -- Extreme Dry Skin Formula -- A gel formula designed to saturate
the stratum corneum, to relieve the symptoms of eczema, dermatitis and extremely
dry skin.

LAM IPM(TM) -- Female Sexual Dysfunction Matrix -- a product that provides
enhanced lubrication while also allowing the external structures of the female
genitalia to be flushed with greater blood supply.

LAM IPM(TM) -- Motion Sickness Matrix -- a product currently under development,
which is a topically applied delivery system, using a patch, of a well-known
motion sickness drug.

LAM IPM(TM) -- Arthritic Pain Matrix -- is a clear aqueous gel that contains a
well proven off patent drug.

For more information please visit our website at http://www.lampharm.com or send
us an e-mail at [e-mail] to receive the latest information and press
releases.

Statements in this press release regarding our business which are not historical
facts are "forward-looking statements" that involve risks and uncertainties
which could cause the Company`s actual results and financial condition to differ
materially from those anticipated by the forward-looking statements. These risks
and uncertainties include, but are not limited to uncertainties relating to the
need for additional funds and corporate partners, product liability, dependence
on third parties for manufacturing and marketing, the early stage of products
being marketed or under development, patent risk and competition.



Press Contact: Barry S. Kaplan

[KaterLudwig]

[HolgiNils]

Auch nicht schlecht...
Doppelt gemoppelt hält wohl besser !

[Escape11]

1:29:17 PM Trade (at Bid) 0.68 100 OTC BB
1:29:11 PM Trade (at Bid) 0.68 500 OTC BB
1:04:08 PM Trade (at Bid) 0.68 4000 OTC BB
1:03:59 PM Trade 0.69 1100 OTC BB
1:03:59 PM Trade 0.69 2900 OTC BB
1:03:36 PM Ask 0.72 2500 OTC BB

[Escape11]

3:52:41 PM Ask 0.72 2500 OTC BB
3:52:41 PM Bid 0.7 2500 OTC BB
3:52:41 PM Ask 0.72 2500 OTC BB
3:52:41 PM Bid 0.7 2500 OTC BB
3:52:37 PM Bid 0.7 2500 OTC BB
3:52:30 PM Trade (at Bid) 0.71 2500 OTC BB
3:50:58 PM Ask 0.72 2500 OTC BB
3:50:58 PM Bid 0.71 2500 OTC BB
3:50:58 PM Ask 0.72 2500 OTC BB
3:50:58 PM Bid 0.71 2500 OTC BB
3:50:48 PM Trade (at Bid) 0.71 5000 OTC BB